Launch Milestones Sample Clauses

Launch Milestones. Subject to the terms and conditions of this Agreement, including Section 7.4, within [***] after the achievement by or on behalf of AbbVie or its Affiliates or Sublicensees of any of the following Milestone Events after the Effective Date during the Term, AbbVie shall pay to Morphic the corresponding Milestone Payment with respect to such Milestone Event on an Indication-by-Indication basis: Milestone Event Milestone Payment [***] [***] [***] [***] [***] [***] Each Milestone Event in this Section 7.2.2 shall be payable once per Indication. For clarity, if a Milestone Event in this Section 7.2.2 is achieved by two (2) or more Licensed Products or Licensed Compounds for the same Indication, such Milestone Event shall only be payable once for such Indication. The maximum aggregate amount of Milestone Payments payable under this Section 7.2.2 by AbbVie with respect to Licensed Products for each Indication is [***].
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Launch Milestones. As to each Licensed Product, Baxalta shall pay to Precision the following non-creditable, non-refundable amounts for the first achievement of the following milestone events for such Licensed Product by Baxalta of any of its Affiliates or Sublicensees (each, a “Launch Milestone”): Launch Milestone Milestone Payment (USD) First Commercial Sale of the Licensed Product in [***] [***] First Commercial Sale of the Licensed Product in [***] [***] First Commercial Sale of the Licensed Product in [***] [***] First Commercial Sale of the Licensed Product in [***] [***] First Commercial Sale of the Licensed Product in [***] [***] First Commercial Sale of the Licensed Product in [***] [***] [***] Each milestone payment set forth in this Section 8.3.2 shall be payable by Baxalta upon the first achievement of the applicable Launch Milestone, and Baxalta shall provide notice to Precision of such achievement within [***] following such achievement. Following Precision’s receipt of a notice described in the immediately preceding sentence, Precision shall provide Baxalta with a corresponding invoice and Baxalta shall pay to Precision the applicable milestone payment described above within [***] after receipt of such invoice.
Sample 1Sample 2
Launch Milestones. (a) Subject to the terms of Sections 6.3.4 and 6.3.5, Licensee will pay Kineta the following one-time event payments (which shall be non-creditable and non-refundable) upon the first Licensed Product achieving the following events:
Sample 1Sample 2
Launch Milestones. Licensee shall notify Company immediately upon the achievement of the milestone event set forth below and shall make the corresponding nonrefundable, non-creditable payment to Company set forth below not later than thirty (30) days from receipt of the relevant invoice issued by Company following Licensee’s notice of the achievement of such milestone event: Milestone Event Payment Amount [***] € [***] [***] € [***] € [***] [***] Notwithstanding the foregoing, Licensee’s failure to notify Company in accordance with this Section 7.3 shall not relieve it of its obligation to make the payments set forth above.
Sample 1
Launch Milestones. Within [**] after the first Launch by Takeda, or an Affiliate or licensee of Takeda of each Pharmaceutical Product in each of (a) Japan, (b) a Major European Country, and (c) the United States of America, Takeda shall pay to Lexicon a launch milestone payment, as set forth below: Launch Event Launch Payment ------------ -------------- First Launch in the first of either Japan, a Major European Country, or the United States of America $[**] First Launch in the second of either Japan, a Major European Country, or the United States of America $[**] First Launch in the third of either Japan, a Major European Country, or the United States of America $[**] For purposes of clarification, notwithstanding anything to the contrary, the maximum amount that Takeda will be obligated to pay to Lexicon pursuant to this Section 5.4 with respect to any single Pharmaceutical Product that is the first Pharmaceutical Product obtained from a single, particular Selected Target will be [**], and Takeda shall have no obligation to pay any amount to Lexicon under this Section 5.4 in excess of [**] with respect to the Launch of such first Pharmaceutical Product; provided, however, that in the event that one or more subsequent Pharmaceutical Products in addition to a first Pharmaceutical Product is obtained by Takeda as a consequence of use of any single, particular Selected Target, the amount to be paid by Takeda to Lexicon upon achievement of any Launch milestone event with respect to any such subsequent Pharmaceutical Product(s) under this Section 5.4 shall be equal to [**] of the amount set forth in foregoing table. The Launch milestone payment under this Section 5.4 shall be paid only once for a single Pharmaceutical Product regardless of formulations or indications. Takeda shall not be required to make the Launch milestone payment for different or additional formulations or indications for the Pharmaceutical Product. For purposes of clarification, Takeda shall have no obligation to make any Launch milestone payment under this Section 5.4 for any Ancillary Diagnostic Product.
Sample 1
Launch Milestones. Within [**] after the first Launch by Lexicon, or an Affiliate or licensee of Lexicon of each Reversion Product (other than Reversion Products licensed to Takeda pursuant to Section 4.6), in each of (a) Japan, (b) a Major European Country, and (c) the United States of America, Lexicon shall pay to Takeda launch milestone payment, as set forth below: Milestone Payment ----------------------------------------------------- Reversion Product identified by Lexicon using a High- Throughput Screening System generated by Takeda and turned over Reversion Product to Lexicon pursuant to licensed by Takeda to Sections 2.2(d) or Lexicon pursuant to Launch Event 2.3(b) and 4.5 Section 2.3(c) ------------ ----------------------- ---------------------- First Launch in the first of either Japan, a Major European Country, or the United States of America $[**] $[**] First Launch in the second of either Japan, a Major European Country, or the United States of America None $[**] First Launch in the third of either Japan, a Major European Country, or the United States of America None $[**] For purposes of clarification, notwithstanding anything to the contrary, the maximum amount that Lexicon will be obligated to pay to Takeda pursuant to this Section 5.6(b) with respect to any single Reversion Product that is the first Reversion Product obtained from a single, particular Released Target will be (i) [**] in the case of a Reversion Product identified by Lexicon using a High-Throughput Screening System generated by Takeda and turned over to Lexicon pursuant to Sections 2.2(d) or 2.3(b) and 4.5 and (ii) [**] in the case of a Reversion Product licensed by Takeda to Lexicon pursuant to Sections 2.3(c), and Lexicon shall have no obligation to pay any amount to Takeda under this Section 5.6(b) in excess of (x) [**] in the case of a Reversion Product identified by Lexicon using a High-Throughput Screening System generated by Takeda and turned over to Lexicon pursuant to Sections 2.2(d) or 2.3(b) and 4.5 and (y) [**] in the case of a Reversion Product licensed by Takeda to Lexicon pursuant to Sections 2.3(c), with respect to the Launch of such first Reversion Product; provided, however, that in the event that one or more subsequent Reversion Products in addition to a first Reversion Product is obtained by Lexicon as a consequence of use of any single, particular Released Target, the amount to be paid by Lexicon to Takeda upon achievement of any Launch milestone event with respect to any...
Sample 1

Related to Launch Milestones

  • Development Milestones Subject to the terms and conditions of this Agreement, no later than [**] following the first occurrence of each event described below (each, a “Development Milestone”), on Product-by-Product basis Moderna shall pay Carisma the non-refundable and non-creditable amounts set forth below for each Product to achieve such event (each, a “Development Milestone Payment”): ​ Development MilestoneDevelopment Milestone Payment (in US$ millions) [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] ​ Moderna shall provide written notice to Carisma of the achievement of each Development Milestone within [**] after such achievement. If a Development Milestone for a Product is achieved without the preceding Development Milestone(s) having been achieved for such Product, then the Development Milestone Payment for such preceding Development Milestone(s) shall be paid by Moderna to Carisma together with ​ ​ the Development Milestone Payment for the Development Milestone that was achieved. For example, if the [**] Development Milestone [**] in the table above is achieved for a Product but the [**] Development Milestone [**] in the table above had not been achieved for such Product, then Moderna would pay the Development Milestone Payment for both such [**] Development Milestone and [**] Development Milestone upon achievement of the [**] Development Milestone. Each of the Development Milestone Payments set forth above shall be payable one time only per Product. If Moderna or its Affiliates or Sublicensees Develops a Product that has achieved at least one Development Milestone and subsequently discontinues Development of such Product and Develops a different Product incorporating or directed to the same combination of Collaboration Targets (whether one Collaboration Target or multiple Collaboration Targets), then Moderna shall be required to pay Development Milestone Payments for such different Product only for Development Milestones that had not been achieved by such discontinued Product.

  • Commercial Milestones In partial consideration of the rights granted by AstraZeneca to Licensee hereunder, Licensee shall pay to AstraZeneca the following payments, which shall be non-refundable, non-creditable and fully earned upon the first achievement of the applicable milestone event:

  • Sales Milestones As to each of the sales milestone events set forth below, GSK shall pay EPIZYME the non-refundable, non-creditable sales milestone payments indicated below upon the first achievement by GSK, its Affiliates or Sublicensees of the success milestone events set forth below with respect to each Selected Target, on a Selected Target-by-Selected Target basis. Sales Milestone Event (For Licensed Products directed to a Selected Target) Milestone Payment (in $ [**]) First Calendar Year in which aggregate world-wide Net Sales of Licensed Product(s) directed to such Selected Target are greater than or equal to $[**] [** ] First Calendar Year in which aggregate world-wide Net Sales of Licensed Product(s) directed to such Selected Target are greater than or equal to $[**] [** ] First Calendar Year in which aggregate world-wide Net Sales of Licensed Product(s) directed to such Selected Target are greater than or equal to $[**] [** ] Upon achievement by or on behalf of GSK, its Affiliates or Sublicensees of a sales milestone event set forth in this Section 6.7, GSK shall promptly (but in no event later than the date on which the royalty report for the Calendar Quarter in which such achievement occurs is due pursuant to Section 6.10.1) notify EPIZYME of such achievement, and GSK shall pay EPIZYME the corresponding sales milestone payment within [**] days after receipt of an invoice for the milestone payment from EPIZYME. Such invoice shall be sent to GSK’s Alliance Manager and [**] with a copy to [**] (or such other email address(es) as may be notified to EPIZYME by GSK). For the avoidance of doubt, more than one of the foregoing sales milestone payments may be earned and become payable with respect to Licensed Products directed to any given Selected Target in the same Calendar Year based on aggregate world-wide Net Sales of Licensed Product(s) directed to such Selected Target during such Calendar Year.

  • Milestones Licensee agrees to use commercially reasonable efforts to meet the milestones as detailed in Schedule 3. In the event that Licensee does not use commercially reasonable efforts to meet any of the milestones, University may at its discretion elect to terminate the licence granted under Clause 2.1 with respect to the relevant Milestones of this Agreement pursuant to Paragraph 7 of Standard Terms and Conditions. No indulgence given by University on any particular occasion shall be deemed or construed as a waiver of its right to terminate this Agreement on future occasions.

  • Regulatory Milestones Celgene shall make the following approval milestone payments to Jounce that are set forth below upon the first achievement by or on behalf of Celgene, its Affiliates or Sublicensees of the regulatory milestone events (“Regulatory Milestone Events”) set forth below with respect to the first Co-Co Product that achieves such event. For clarity, each milestone set forth below shall be due and payable one time only (regardless of the number of Co-Co Products to achieve any such Regulatory Milestone Event). CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Regulatory Milestone Event (For the first Co-Co Product that achieves such event) Milestone Payments (in $ millions) [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] [***] For each of Paragraphs (1) - (3) of this Exhibit C-1, the Parties understand and agree that in no event will more than one (1) milestone payment be paid with respect to any specific event triggering a payment under this Jounce Lead Co-Co Agreement.

  • Milestone An event associated with a specific date, for which a payment will be due, as set out in the Payment Schedule of any Project Agreement.

  • Milestone Event Milestone Payment [***] [***]

  • Development Milestone Payments In partial consideration for the rights and licenses granted to Coya hereunder, within ten days after the first achievement of each milestone event in a given Indication set forth in this Section 5.2 (Development Milestone Payments) with respect to a Product (each, a “Development Milestone Event”) by or on behalf of Coya or any of its Affiliates or Sublicensees, Coya shall provide ARScience Bio written notice to ARScience Bio identifying the Development Milestone Event achieved. Upon receipt of any such notice of first achievement of a Development Milestone Event by Coya or its Affiliates or Sublicensees, ARScience Bio will promptly invoice Coya for the applicable Development Milestone Event and Coya will make a milestone payment to ARScience Bio in the amount set forth in this Section 5.2 (Development Milestone Payments) corresponding to such Development Milestone Event (each, a “Development Milestone Payment”) within 45 days of receipt of such invoice. On an Indication-by-Indication basis, each Development Milestone Payment shall be payable only upon the first achievement of the corresponding Development Milestone Event by a Product, in any given Indication for which the Development Milestone Events have not been previously achieved (each such Indication, a “New Indication”). No amounts shall be due for subsequent or repeated achievements of such Development Milestone Event with respect to the same or different Mono Product or Combination Product, as applicable, in such Indication. Accordingly and for clarity, the Development Milestone Payment shall be paid only once, when first achieved by Coya, an Affiliate or a Sublicensee, but no payment shall be due if the same milestone is subsequently achieved by one of Coya, an Affiliate or a Sublicensee. For clarity, the amounts owed in Column (a) below shall be due for the first Combination Product to achieve the Development Milestone Events in a New Indication and the amounts owned in Column (c) below shall be due for the first Mono Product to achieve the Development Milestone Events in a New Indication. Any Combination Product or Mono Product to achieve the Development Milestone Events in a New Indication after the first achievement of the Development Milestone Events as described in the foregoing sentence will cause the amounts in Column (b) with respect to a Combination Product and Column (d) with respect to a Mono Product to be due and payable by Coya upon each such occurrence. If the first Product to achieve a Development Milestone Event in any Indication is a Combination Product, the amounts in Column (a) below shall be due and payable by Coya. If the next Product to achieve a Development Milestone Event in a New Indication is a Mono Product, the amounts in Column (c) below would be due and payable by Coya; provided, that if such next Product to achieve a Development Milestone Event in a New Indication is a Combination Product, the amounts in Column (b) would be due and payable by Coya. By way of example, if a Combination Product achieves IND Acceptance in ALS, and is the first Product to achieve a Development Milestone Event under this Agreement, [***] will be due and payable by Coya. If subsequently a Mono Product achieves IND Acceptance in ALS, no Development Milestone Payments will be due and payable by Coya under this Agreement. However, if subsequently any Combination Product achieves IND Acceptance in Alzheimer’s disease, [***] would be due and payable by Coya.

  • Development and Regulatory Milestones With respect to each of the following milestones, Ikaria shall pay BioLineRx the corresponding payment set forth below within [**] days after the achievement by Ikaria, its Affiliates or Licensees of such milestone: MILESTONE PAYMENT

  • Commercial Milestone Payments Green Cross shall pay to MacroGenics the Net Sales milestone payments set forth below, which shall be due and payable within *** after the end of the first Calendar Year during which such milestone is triggered.

Time is Money Join Law Insider Premium to draft better contracts faster.